A Systematic Biomedical Perspective on COVID-19 Pandemic: From Detection to Vaccination


Department of Chemistry, Islamic University of Science and Technology, Awantipora, India
E-mail: mirjanmohammad@gmail.com

Received: 8 September 2021; Revised: 30 November 2021; Accepted: 9 December 2021

Abstract: The year 2020 witnessed a challenging period for worldwide scientists to find a suitable treatment for the deadly novel coronavirus infectious disease-2019 (nCOVID or COVID-19). The entire scientific community has been eager to develop effective vaccines and medicine against COVID-19. Despite the fact of administration of vaccination in several countries across the globe, the drug repurposing of several antiviral compounds yielded satisfactory results in recovering the affected people. As it is a known fact that vaccination alone is not the end of this pandemic, but the final treatment in terms of drugs/medicines specific to this disease is yet underway. It looks worthwhile to present a literature survey based on the collective information related to the drug candidates that have been repurposed, the respective theoretical evaluation, and some of the effective therapies usable in treating COVID-19. This review also describes diagnosis and vaccination availed so far. Therefore, a sequential literature extract is hereby presented starting from the detection, going through virulence, drug repositioning, virtual screening, and the final destination in the form of vaccine development. A few commercially available vaccines have also been introduced. Based on the survey, it is clear that the entire world must remain alert for any future pandemic keeping in view the successful and unsuccessful efforts practiced in the COVID-19 pandemic.

Keywords: corona, COVID-19, drug repurposing, docking, therapies, density functional theory

1. Introduction

A large number of causalities happened worldwide with the outbreak of novel coronavirus infectious disease-2019 (nCOVID or COVID-19). After being declared as a pandemic, an emergency was declared globally in response to the rapid transmission and increased number of deaths. Even though vaccination for coronavirus has been started, but no specific treatment has been yet found for this disease. Though the human immune system is the real defense to combat this disease, the use of some known antiviral drugs has been repurposed for the treatment of coronavirus infection [1].

Due to the rapid transmitting feature, high pathogenicity and genetic composition matching with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), the infection has been termed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. The actual origin of this dreadful virus is yet unknown, though the human-to-human transfer of novel coronavirus is widely known. Therefore, preventive measures in the form of social distancing and sanitization received immense attention worldwide. Despite these strategies depending on geographical location and
living standards, but have proven helpful in breaking the spreading chain of this infection [3]. Meanwhile, antiviral and anti-inflammatory drugs have been repurposed as a way to treat infected people. Hence, due to the absence of the availability of any COVID-19 specific drug, the use of some broad-spectrum antiviral drugs has been practiced worldwide and is generally referred to as drug repurposing.

The innate responsive property of the human body towards microbial invasions, heat shock, or toxin intervention is mainly dealt with immune system, expresses in some symptomatic forms including inflammation, color change, heat, etc. The inflammation is usually associated with the releasing of histamine, bradykinin, and prostaglandins by the affected tissue or cellular region, inducing blood vessels to leak fluid into the belonging tissues and finally causing swelling in the respective portion. Non-steroidal anti-inflammatory drugs (NSAIDs) are usually administered to control and reduce inflammation. These administered drugs include both the types of inhibitors viz., selective as well as non-selective. Rofecoxib, valdecoxib, celecoxib, etc., are the selective cyclooxygenase-2 (COX2) inhibitors, and on the other hand ibuprofen, aspirin, diclofenac, and naproxen are non-selective. In COVID-19, these mechanistic pathways in selecting suitable drugs for the treatment have raised concerns over the possible increasing adverse effects [4, 5]. Several shreds of evidence indicate NSAID’s role for COVID-19 treatment, however, in respect to this viral strain and the mutations that go on in the virus, it needs to be controlled under high order precautions [6]. Many antimalarial drugs (like chloroquine) [7] and several other broad-spectrum antiviral drugs have been repurposed to treat infected people. This antiviral mechanism has been diagnosed with increased endosomal pH and inhibition of the glycosylation of severe acute respiratory syndrome coronavirus (SARS-CoV) [8, 9]. Therefore, chloroquine, arbidol, dexamethasone, etc., have found emergency use against the infection, and satisfactory results were gained [10-14].

In the conspicuous fascination towards COVID-19 investigations and our continuous interest, this review was aimed to sum up the COVID-19 pandemic sequential stages to derive the past, present and future directions of this disease. The challenges that the analytical front has met during the pandemic, drug repurposing, theoretical scientific role, and the stage of vaccination have been highlighted in this article.

2. COVID-19 pandemic outbreak and SARS-CoV-2 virulence

In December 2019, the novel coronavirus infection was first detected in Wuhan, Hubei Province, China. As of now this infectious disease is widely known as COVID-19 or nCOVID and has been widely spread in the whole world [15]. On 31st December 2019, high authorities of China alerted World Health Organization (WHO) with an alarming signal conveying the outbreak of a new strain of coronavirus, responsible for severe illness similar to SARS-CoV-1, and was hence named as SARS-CoV-2. COVID-19 is currently considered a high transmitting infectious disease. Though the actual source of this infection is unknown yet, the high communicability and millions of deaths by this disease defeated the whole world. Albeit the dynamics are not clear yet, several assumptions have been made showing the virus to have an animal origin [16].

The coronavirus has been found to have an elliptic or round shape and is mostly referred to as pleomorphic (in microbiology, pleomorphic microorganism is the capability to change morphology, functional status, or modes of reproduction with respect to environmental conditions). The virus has a diameter of 60-140 nm approximately. Generally, coronaviruses are ultraviolet (UV) and heat-sensitive. The genetic analysis has shown a resemblance of 86% of the whole genome of SARS-CoV-2 with SARS-CoV-1 [17]. Studies conducted on seeking the mechanistic details of SARS-CoV-2 virulence have confirmed the respective affinity towards the functional behavior of the structural proteins (SP) and nonstructural proteins (NSPs). For example, the underlined research indicated that NSPs possess the ability to impair and affect the innate immune response of the host [18].

Figure 1 displays the structural diagram of the virus along with the SP and NSPs parts. The main part of the virus involved in pathogenicity is its envelope because it is the key supporting assembly for viral release. Secondly, the biological interaction through specific enzyme intervention viz., the angiotensin-converting enzyme-2 (ACE2) located on the lower respiratory tract cells of humans, has a direct link for receptors to conduct endocytosis for SARS-CoV-2 in COVID-19 [19]. Among the different structural components of the virus, the constituent spike (S) glycoprotein mainly consists of S1 and S2 subunits. The S protein homotrimeric are arranged on the surface of the virus wholly termed as envelop that represents the leading ink used for host receptor susceptibility. The S2 subunit is highly conserving for being a site of fusion peptide along with the transmembrane domain and the cytoplasmic region. Therefore, for
designing anti-coronavirus agents, S2 is the main target to deactivate. Other SP is found only in COVID-19 causing viruses, including open reading frame (ORF) encoded proteins, ORF3b and ORF8 [20]. The latest research on receptor-binding domain (RBD) part of the virus S proteins reveals efficiently targeting feature of the ACE2 receptors at the molecular level. These receptors have a key role in blood pressure maintenance. The SARS-CoV-2 S protein has got such an effective binding potential with the human cells; such that the entire world community of scientists remarked this as a result of natural selection with no implications of genetically engineered products [21].

![Viral structure of COVID-19 causing virus](image)

**Figure 1.** Viral structure of COVID-19 causing virus [22: p.11]

### 3. COVID-19 diagnosis

With the novel coronavirus pandemic, many concerns regarding the detection of this disease have emerged. The COVID-19 diagnosis is usually done using real-time polymerase chain reaction (RT-PCR). RT-PCR method refers to a nuclear-based detection of genetic material present in any sampled substance including a virus. Previous versions of this instrument were principally involving radioactive isotopic effect marking agents to find the information of a particular genetic analyte, but due to subsequent refining isotope labeling was replaced with special markers, most often which are fluorescent dyes. The technique furnishes the results immediately. This technique has found a wide range of use for detecting the novel coronavirus infection. Like drug repurposing for COVID-19, instrumental repurposing in the form of
RT-PCR which was earlier used for diagnosing Ebola and Zika viral infections supported to a maximum in diagnosing COVID-19 infection [23].

Because of the scarce access to equipment, reagents, and less target specific, the test is not much reliable [24-26]. Based on the requirement of accuracy, patient care and medicine, such diagnostics must be less time-consuming and more reliable. Therefore, test sensitivity, cost and time taken by routine techniques have forwarded quests to the scientific community to search for more sensitive and high economic ways of detection. Mass spectrometry, Raman, infrared, etc., like techniques have been suggested to solve these issues [27, 28]. Similarly, biosensing detection based on field-effect transistor (FET) has been suggested as high sensitive diagnostic method using immunological concept [29]. Some coupled techniques like ultra-high-pressure liquid chromatography hyphenated with high-resolution mass spectrometry (UHPLC-HRMS)-based have also been suggested in this context [30]. Therefore, the on-time detection along with clinically satisfied specificity and sensitivity is the most important forefront in COVID-19 detection analysis. It is expected that spectroscopic analysis can be a promising detection way using the potential chemical biomarkers [31, 32].

The expression of proteins or enzymes associated with COVID-19 severity or death could be assigned as markers of the infection. These include D-dimer for blood coagulation, lactate dehydrogenase indicative of cell damage and C-reactive protein showing the inflammatory response. An accumulation of evidence relating to COVID-19 with the severe acute respiratory syndrome (SARS) suggests that protein biomarkers could define these investigations [33]. From the identity of their absorption and emission bands, it can be possible to find the extent of infection. The consistency of different vibrational and rotational modes in bioaerosols like coronavirus has been proposed as useful in presence of a light-sensitive material [34]. In due course, even smartphone-assisted electrochemical signaling has also been suggested as a detective device [35]. Optical theranostics could identify the pulmonary severity of COVID-19 easily [36]. Non-contact nanomaterial-based optical methods have been reported to help in both the detection as well as surface disinfection of coronavirus [37]. Therefore, interaction with light is suitable for both detection as well as disinfection even if present in trace concentrations [37, 38].

4. Antiviral drug repurposing as the treatment option in COVID-19 pandemic

COVID-19 apocalyptic times witnessed emergency use of known antiviral drugs in addition to other precautionary measures including sanitization and physical distancing. The clinical and nonclinical investigations made in the same period indicate a satisfactory recovery rate using the drugs that were earlier found effective against several viral diseases. This administration of drugs is generally known as drug repurposing. The drugs that found emergency repurposing have been discussed below.

4.1 Hydroxychloroquine and chloroquine

After the widespread of COVID-19, many antiviral, anti-inflammatory, and antimalarial drugs were used as emergency medicine [39] because of the unavailability of COVID-19 specific medicine. Despite numerous side effects of hydroxychloroquine, the drug when used in nCOVID patients showed positive results to a considerable extent [40]. In the course of the administration, researchers have been continuously studying the efficacy, safety and other mechanistic pathways involved in treating COVID-19 patients [41]. Results indicate that the hydroxychloroquine-based treatment had reduced the fatality rate among the nCOVID patients as compared to those patients who were not treated with this drug [42]. The administration of zinc supplements and azithromycin in addition to hydroxychloroquine has shown a remarkable increase in the recovery rate [43]. Albeit the safety concern [44-46], this triple-drug combination has been reported as an effective COVID-19 treatment [47]. The repositioning of this drug thus faced several critics for safety purposes [48], but in the drug emergency, chloro- and hydroxychloroquine were tremendously used to treat COVID-19 patients [49]. Both these drugs have been found to change the pH and create misinformation of viral proteins. The drugs were already in use to treat the different viral diseases like Ebola, influenza, human immunodeficiency virus (HIV), etc. Several mechanistic pathways have been proposed for their antiviral action and certain questions are under investigation [50], but recent studies have revealed that hydroxychloroquine restricts the replication process of the SARS-CoV-2 virus [51, 52].
Other suggestions like inhibition of the importin (IMPα/β1) and acidotropic lipophilic weak base behavior by hydroxychloroquine have also been mentioned in the mechanistic studies. The structures of both forms of chloroquine have been given in Figure 2.

![Figure 2. 3D structures of (a) chloroquine and (b) hydroxychloroquine (Drawn in GaussView5.0)](image1)

4.2 Favipiravir

Favipiravir represents another significant antiviral drug that is mainly found in oxo and hydroxy forms (Figure 3). This drug has been repurposed for COVID-19 treatment in most countries including India. This antiviral drug is specific to the influenza virus. As prolonged use of this drug increases the uric acid level in blood which in turn affects the kidney functioning, and hence, favipiravir cannot be administered for a long time [53]. The repositioning of favipiravir for nCOVID has shown a good response when compared with the repurposing of other antivirals including lopinavir and ritonavir. The use of this drug in the coronavirus infection has indicated a significant improvement in chest complications and decreasing the viral load [54]. The mechanistic details reveal that the favipiravir drug blocks the replication of ribonucleic acid (RNA) viruses and hence, good results are expected against the COVID-19 infection while administering this drug [55].

![Figure 3. 3D structural representation of (a) hydroxyl favipiravir and (b) oxo favipiravir (Drawn in GaussView5.0)](image2)
4.3 Remdesivir

Remdesivir is another RNA polymerase inhibitor with high power of antiviral activity and hence able to act against coronavirus. In recent randomized trials conducted to find the effective dosage of this drug against nCOVID patients, the results have shown good effects in the dosage uptake of 100-200 mg daily, while a 5-10 mg/day dose showed no significant difference [56]. Similar observations in a placebo-controlled trial of intravenous remdesivir in adults with confirmed infection were given 200 mg on day 1, then 100 mg daily for up to 9 or 10 days. This administration has shown shortening the recovery time [57]. Some of the side effects expected from this drug urge the scientific community to seek for safety and efficacy of such drugs [58]. Some assumptions like drug combination and intervention of Chinese herbal medicines along such treatment strategies have received considerable attention to curtail the physiological abnormalities like cytokine storm - a major cause of deaths [59, 60]. Figure 4 shows the 3D structure of this drug.

![Figure 4. 3D structure of remdesivir (Drawn in GaussView5.0)](image)

4.4 Lopinavir and ritonavir

Because of the emergency use of antiviral drugs for COVID-19 treatment, the benefit-risk profile for lopinavir-ritonavir (Figure 5 and Figure 6) is still underway to further study its efficacy and effectiveness [61]. The repositioning of these drugs from their use for the treatment of SARS-CoV-1 to SARS-CoV-2 has been found beneficial in emergency treatment despite lower antiviral efficacy as compared with arbidol [62]. Hence, drugs like lopinavir and ritonavir should be further investigated to avail permission from the US Food and Drug Administration (FDA) for safety concerns [63, 64]. In due course, some trials for such therapies have got scientific concerns involving six trials for lopinavir-ritonavir and several other trials for other drugs [65]. The mechanistic details of lopinavir-ritonavir for SARS-CoV-2 treatment indicates binding property with ACE2 and also potent protease inhibition to inhibit replication of the viral RNA [66].
Figure 5. 3D structure of lopinavir (Drawn in GaussView 5.0)

Figure 6. 3D structure of ritonavir (Drawn in GaussView 5.0)
5. Other therapeutic options

Therapy, in general, may be defined as the remediation attempt of any health-associated problem by following the diagnostic ways. In the usual medical sense, the term signifies treatment. In addition to several drug therapies (antiviral repurposing) as discussed above, some of the commonly known therapies applicable for COVID-19 treatment have been discussed below.

5.1 Ozone therapy

The respiratory system is mainly involved in the gaseous exchange phenomenon of normal physiological functions. The virus that causes respiratory issues can produce symptoms including cold, pneumonia, fever, etc. At the same time, the immune response in the form of inflammation is the main symptom behavior of virus invasion. The use of new therapies like ozone therapy (OT) represents one of the best options to stop inflammation [67]. Earlier studies involving OT have shown satisfactory results for the treatment of gastrointestinal inflammations despite the unknown mechanism behind this treatment option [68]. However, based on different experimental studies it has been revealed that ozone (O₃) enhances antioxidant activity and hence, retards the mucosal damage of the intestine [69]. In medicine, OT involves the use of a combination of O₂ and oxygen (O₂), producing a series of effects over pathology state and medical practices. By this technique, tissues can be oxygenated in a better way and decrease the lung inflammation to regulate the respective immune response [70]. O₃ is a strong oxidizing agent and can thus be used to disinfect viral infection [71]. Ozonation could result in a decrease in viral load [72].

In special reference to COVID-19, four significant properties have been linked with OT. These include the effects of O₃ in improving gas exchange, reducing inflammation, modulating antioxidative behavior, and inactivating the virus. In previous reports, the therapy has shown good results against the Ebola virus [73]. The anti-inflammatory response of this therapy could be assumed as the main reason for the use in nCOVID patients. OT has been reported to protect ischemia-reperfusion injury (IRI) and therefore should be investigated in relevance to COVID-19 [74]. Several studies related to the mechanism of action of OT, the respective physiological impact, and cytoprotective roles are supportive to suggest OT as a therapeutic option for the treatment of COVID-19 patients [75]. Also, some experimental studies invoking the in vivo tests of coronavirus infected patients using OT have found this therapy beneficial in improving lung capacity, normalizing the redox potential, and also the activation of heme oxygenase (HO-1) [76]. Similar observations of the beneficial role of OT have been reported in recent case reports where O₃ has been found a potent anti-inflammatory tool [77]. Though some health supplements are also necessary addition for the COVID-19 treatment [78], the powerful antioxidant potential of O₃ has been suggested the key factor to increase O₂ in the blood and other tissues, showing profound implications in glycolysis, Krebs cycle, subcellular role in the mitochondrial antioxidative pathway and anti-inflammatory response in cytokines [79]. Therefore, in a special focus on using OT for SARS-CoV-2 treatment may also be understood by looking at the cellular interaction of O₃ with the coronavirus. Many viruses need a reduced form of sulfhydryl functionality for cellular fusion, but these functional groups are vulnerable to oxidation [80], and hence OT may disinfect the virus in this way [81, 82].

5.2 Plasma therapy

During emergency times in the COVID-19 pandemic, this type of therapeutics played a prominent role in recovering the suffered patients. Even intensive care unit (ICU) admitted patients responded well to plasma exchange therapy [83]. Plasma therapy (PT) involves the use of convalescent plasma of recovered patients for the treatment of newly infected patients [84]. Earlier reports of using the same therapy in treating influenza A virus subtype H1N1 infection indicate successful eradication of the cytokine storm and rectifying the lung functioning, and therefore the same expectation was felt for the emergency treatment of COVID-19 [85]. The administration of PT has been in practice since the 1900s for the treatment of emerging infections and the efficacy of such therapies has been found based on the associated polyclonal neutralizing antibodies [86]. Several PT-administered successful stories got published in this context. In one such report, one COVID-19 patient recovered completely after giving two successive convalescent PTs [87]. Thus, passive immunization plays a key role in treating such viral infections [88].

In order to find the role of blood components in PT, some studies performed total blood cell analysis of PT-treated
COVID-19 patients. A significant difference was noticed in all the blood components [89]. PT hence proved effective in saving precious lives when an emergency was declared in the COVID-19 pandemic [90]. Many studies related to the effect of the therapy report that the planned therapy dose ranges from 200-800 mL [91]. This therapeutic option appeared fascinated for the treatment of COVID-19, but the questions arising for the determination of real mechanisms and efficacy are still on the screen [92].

5.3 Nitric oxide therapy

Viral invasion in the human body creates the overproduction of free radicals, like in other pathogenic states including cancer, heart, diabetes, hypertension, etc [93]. The same happens in the COVID-19 infectious state [94]. These reactive species affect physiological homeostasis [95]. Among several such chemical species, nitrogen reactive free radicals have a profound role in cytokine regulation immunomodulation and various cell signaling pathways [96]. In the case of the imbalance of oxidants, harmful effects arise and oxidation stress gets created [95, 96]. Oxidative stress has been the main cause of COVID-19 deaths especially comorbid deaths [97, 98]. Therefore, the treatment of coronavirus infectious state in addition to other options including nitric oxide (NO) therapy has been suggested as a good option to functionalize the affected lungs, decrease the viral load, control cytokine storm, and kill the virus. R-107 and COViNOX are the two familiar NO-based prodrugs for COVID-19 treatment. Many scientific reports insist the use of NO-therapy and the mechanism of action, especially on nCOVID treatment is under vigorous investigation [22]. In addition to the above, the potential of NO to boost immunity might prove worthy in formulating the final specific medicine and vaccine for nCOVID [99]. As far as the NO-therapy-based mechanism is concerned, both the S protein fusion and halting of RNA replication have been proposed, as shown in Figure 7.

Figure 7. NO-mediated anti-coronavirus activity [22: p.13]

5.4 Aromatherapy

The use of essential oils in the form of extracts obtained from herbal plants, flowers, etc., as a treatment for several diseases has been in practice for many years ago in many countries including India, Egypt, and especially in Europe. The term aromatherapy (AT) itself reflects its meaning concerning aromatic products or plants [100]. This has been widely accepted that essential oils are potent anti-inflammatory, bronchodilatory, immunomodulatory, and antiviral candidates. Therefore, it is logical to have a similar potential for SARS-CoV-2. Also, due to the presence of active phytochemicals in essential oils, it helps to reduce the viral load by showing anti-coronaviral activity in multiple stages. The primary positive impact on the host’s respiratory tract suggests that the AT option can effectively treat COVID-19 infection [101].
5.5 Photodynamic therapy

Photodynamic therapy (PDT) mainly involves a light-driven modern technique that uses photosensitizer as an excitation source for the formation of reactive species. Light-based therapy can also be suggested as another option for the treatment of SARS-CoV-2. The therapy is especially applicable for cancer treatment and killing microbes from surfaces, air, wastewater, air, etc [102]. Such a disinfecting approach can be suggested for COVID-19 treatment as well.

6. Role of molecular simulation in speculating the COVID-19 treatment

In the main SARS-CoV-2 period, experimental investigations were not so easy to deal with the deadly virus. Hence, the direct practical examinations were mostly replaced by computational studies to speculate on the structure-activity relationship between so many natural and synthetic compounds and reported coronaviruses. Despite social distancing and administrative lockdowns, theoretical chemistry put forth potential views to find the efficacies of drugs repurposed for COVID-19 treatment. This section has been highlighted under two heads viz., density functional theory (DFT) approach and molecular docking.

6.1 Density functionalized status of COVID-19 drugs

DFT is the prominent theoretical tool in elucidating quantum chemical-based molecular descriptors. This theory is applicable almost in every field of research. Presently, in the COVID-19 pandemic times, the repurposed drugs have generated a ray of hope for the treatment. However, it looks prime concern to find the drug efficacy of these candidates based on theoretical calculations. DFT-based speculation has recently suggested silver-carbene complexes as potential candidates to prevent SARS-CoV-2 viral infection [103] and the probable mechanism may be sought from the determination of non-covalent interactions with main proteases [104]. Among several reactive descriptors useful for such studies, DFT-based estimation to find parameters related to thermal analysis, dipole tensors, and coulombic potentiality has a profound effect to elaborate the anti-COVID-19 drug properties [105]. Such efforts have yielded approaches to design COVID-19 treatment lead compounds [106]. Similar promising results have been reported and several amino acids have been declared as effective anti-COVID-19 candidates [107]. The density functional aspects reported for remdesivir-repurposed anti-COVID-19 drug serve as fine tools to understand its inhibiting potential against SARS-CoV-2 genetic polymerase [108]. Similar simulation studies of 2-[N-(carboxymethyl)anilino] acetic acid (PIDAA) have been reported for the evaluation of its reactive properties in finding its application for COVID-19 treatment [109].

In addition to the reactive descriptors, the computational results confined to binding energies using DFT have been used to find the drug binding affinity of several influenza medicines, to reach a better predictive approach for SARS-CoV-2 treatment [110, 111]. Not only enzyme interaction can be sought from DFT, but also the drug adsorption studies which help design drug potencies [112]. The combination of the DFT method with molecular docking represents a fine approach for more sound speculation of drug designing [104, 113]. The studies of molecular interaction with enzyme active sites should, first of all, involve geometry optimization using DFT. Therefore, to go for molecular docking studies to reveal COVID-19 treatment, the initial DFT-based optimization is a necessary step. For example, an exhaustive study conducted by Hagar et al. first studied four main compounds: (i) favipiravir, (ii) amodiaquine, (iii) 2’-fluoro-2’-deoxyctydine, and (iv) ribavirin theoretically at DFT level, and followed by the docking revealing DFT parameters (Table 1) could share with the different extent to significantly affect the binding affinity of these drugs to the active protein sites [105]. The parameters given in Table 1 are calculated by solving the following equations:

\[ \Delta_{\text{LUMO-HOMO}} = E_{\text{LUMO}} - E_{\text{HOMO}} \]  

(1)

\[ \chi = \frac{-(E_{\text{HOMO}} + E_{\text{LUMO}})}{2} = \frac{(I + A)}{2} \]  

(2)
\[ -E_{\text{HOMO}} = 1 \]  \hspace{1cm} (3)

\[ -E_{\text{LUMO}} = A \]  \hspace{1cm} (4)

\[ \eta = \frac{(E_{\text{LUMO}} - E_{\text{HOMO}})}{2} \]  \hspace{1cm} (5)

\[ \omega = \frac{\mu^2}{2\eta} \]  \hspace{1cm} (6)

\[ \delta = \frac{1}{\eta} \]  \hspace{1cm} (7)

Table 1. Calculated electronegativity (\(\chi\)), global hardness (\(\eta\)), softness (\(\delta\)), global electrophilicity index (\(\omega\)), ionization potential (\(I\)) and the electron affinity (\(A\)) in eV of investigated compounds i-iv \[105 : \text{p.4}\]

<table>
<thead>
<tr>
<th>Drug</th>
<th>(E_{\text{HOMO}})</th>
<th>(E_{\text{LUMO}})</th>
<th>(\Delta E)</th>
<th>(\chi)</th>
<th>(\eta)</th>
<th>(\delta)</th>
<th>(\omega)</th>
<th>(I)</th>
<th>(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>i</td>
<td>-7.61</td>
<td>-5.47</td>
<td>2.14</td>
<td>2.06</td>
<td>1.07</td>
<td>0.94</td>
<td>2.27</td>
<td>7.61</td>
<td>5.47</td>
</tr>
<tr>
<td>ii</td>
<td>-5.65</td>
<td>-1.65</td>
<td>4.00</td>
<td>3.70</td>
<td>2.00</td>
<td>0.50</td>
<td>13.69</td>
<td>5.65</td>
<td>1.65</td>
</tr>
<tr>
<td>iii</td>
<td>-6.34</td>
<td>-1.05</td>
<td>5.28</td>
<td>3.65</td>
<td>2.64</td>
<td>0.38</td>
<td>17.59</td>
<td>6.34</td>
<td>1.05</td>
</tr>
<tr>
<td>iv</td>
<td>-7.22</td>
<td>-1.68</td>
<td>5.54</td>
<td>3.04</td>
<td>2.77</td>
<td>0.36</td>
<td>12.80</td>
<td>7.22</td>
<td>1.68</td>
</tr>
</tbody>
</table>

6.2 Molecular docking as the main theoretical approach in finding nCOVID treatment

The uncontrolled number of deaths caused by COVID-19 and its rapid transmission resulted in the proclamation of WHO to declare this disease as pandemic [114]. The entire scientific world started working on this new infection. Meanwhile, molecular simulation studies in the form of computational docking served as the best tool to predict the structure-activity relations of previously used antiviral drugs [115]. By the intervention of such studies, lopinavir, ritonavir, oseltamivir, ribavirin, and many other drug candidates began to be repurposed for the treatment of SARS-CoV-2 disease [116, 117]. Computational chemists began to interrogate other types of compounds including synthetic as well as natural to depict an effective nCOVID drug [118-121]. For instance, among the drugs that are being tested in clinical trials for COVID-19, danoprevir and darunavir have the highest binding affinity to the target main protease of SARS-CoV-2. Saquinavir and beclabuvir were identified as the best novel candidates for COVID-19 therapy by using virtual screening of drugs approved for other clinical indications.

The computationally evolved protein-ligand interactions to predict the effectiveness of several repositioned drugs against SARS-CoV-2 have been shown to possess a potential inhibitory action [122]. For hydroxychloroquine, molecular docking and simulation evaluation also shows well fascinating docking score against the SARS-CoV-2 proteases, revealing the structural framework of the key residues [123]. Similar studies upon some of the drugs approved by the FDA that have been used in past epidemics indicate that out of ten selected drugs, brincidofovir is considered the highest antiviral drug for the treatment of COVID-19 [124]. In a similar sense, natural products like piperine, capsaicin, piperine, and curcumin have been shown to have the capability of effective interactions with the viral proteases [125]. Therefore, the main computational approach in the form of docking analysis proved helpful at the times when only lockdown and physical distancing were felt necessary to curb the pandemic.

7. Development COVID-19 vaccine: final destination before a specific medication

In medical terminology, a vaccine may be defined as a source of active acquired immunity prepared under
biological requirements for a specific type of infection. The composition of a vaccine resembles typically that of a microorganism that causes the infection and the selection of material is done very carefully so that microbial deactivated or in killed form, or any other related surface proteins are allowed to be the part of the vaccine. As of now, the world community is carrying out a vaccination drive for COVID-19. At the times when there was no human vaccine available in the market, several strategies to treat and curb this dreadful infectious disease were only the source of protection. The combinatorial results of experimental and theoretical scientists have led to a successful launch of a final trial of the vaccination against COVID-19 [126].

Coronaviruses as discussed have positively-stranded RNA with its genetic material packed within the nucleocapsid (N) protein and covered by specific proteins viz., membrane (M) protein, envelope (E) protein, and the S protein [127]. Earlier, in the development of a vaccine, different SP were targeted, most of these studies ceased after the SARS and Middle East respiratory syndrome (MERS) outbreaks. But with the recent pandemic outbreak, it was felt urgent to resume the work on this vaccine research. As a result, on March 16, 2020, the first series of trials to test these S protein-targeted coronavirus vaccines (messenger RNA based) in humans began on a preferential basis (ClinicalTrials.gov Identifier: NCT04283461) (Table 2) [128].

### Table 2. Reported SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 vaccine clinical trials [128-137]

<table>
<thead>
<tr>
<th>Virus</th>
<th>Location</th>
<th>Phase</th>
<th>Year</th>
<th>Identifier</th>
<th>Vaccine Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV</td>
<td>United States</td>
<td>I</td>
<td>2004</td>
<td>NCT00099463</td>
<td>Recombinant DNA vaccine (S protein)</td>
</tr>
<tr>
<td>SARS-CoV</td>
<td>United States</td>
<td>I</td>
<td>2007</td>
<td>NCT00533741</td>
<td>Whole virus vaccine</td>
</tr>
<tr>
<td>SARS-CoV</td>
<td>United States</td>
<td>I</td>
<td>2011</td>
<td>NCT01376765</td>
<td>Recombinant protein vaccine (S protein)</td>
</tr>
<tr>
<td>MERS</td>
<td>United Kingdom</td>
<td>I</td>
<td>2018</td>
<td>NCT03399578</td>
<td>Vector vaccine (S protein)</td>
</tr>
<tr>
<td>MERS</td>
<td>Germany</td>
<td>I</td>
<td>2018</td>
<td>NCT03615911</td>
<td>Vector vaccine (S protein)</td>
</tr>
<tr>
<td>MERS</td>
<td>Saudi Arabia</td>
<td>I</td>
<td>2019</td>
<td>NCT04170829</td>
<td>Vector vaccine (S protein)</td>
</tr>
<tr>
<td>MERS</td>
<td>Germany, Netherland</td>
<td>I</td>
<td>2019</td>
<td>NCT04119440</td>
<td>Vector vaccine (S protein)</td>
</tr>
<tr>
<td>MERS</td>
<td>Russia</td>
<td>I, II</td>
<td>2019</td>
<td>NCT04128059</td>
<td>Vector vaccine (protein not specified)</td>
</tr>
<tr>
<td>MERS</td>
<td>Russia</td>
<td>I, II</td>
<td>2019</td>
<td>NCT04130594</td>
<td>Vector vaccine (protein not specified)</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>United States</td>
<td>I</td>
<td>2020</td>
<td>NCT04283461</td>
<td>mRNA-based vaccine (S protein)</td>
</tr>
</tbody>
</table>

As S protein is the main crucial mediator in virus entry, and hence in the SARS vaccine development, this full-length protein (with S1 subunit: main receptor) have been sought as the main antigens for the vaccine development for referred. This is mainly due to its significance in neutralizing antibodies that prevent host cell infection. Despite all this, studies have shown that among viral proteins, S protein targeted vaccination is not fully protective because of some safety concerns [138, 139]. Meanwhile, significant research was conducted to generate efforts for developing more efficacious COVID-19 vaccines [140]. For instance, reverse vaccinology (RV) in this context has put promising candidates for vaccine by employing bioinformatic analysis over the pathogenic genome. RV appears to have successfully applied the same to vaccine discovery, including Group B meningococcus that led to licensing Bexsero as a vaccine [141].

The Russian Direct Investment Fund (RDIF), since the start of the COVID-19 pandemic, has played a key role in fighting the virus in Russia and played the main role in bringing up SPUTNIK V as a vaccine for COVID-19. Recently, Moderna’s CEO also announced that the final form of its vaccine has 94 percent efficacy. By the 18th of December 2020, the Moderna Vaccine was granted FDA approval. Beijing Institute of Biological Products, Sinopharm is also testing its vaccine almost in the final phase. Previously, AstraZeneca, also in the final phase of work, reported that their FDA-authorized vaccine produces a strong immune response in a clinical trial involving people over the age of 70 [142]. Meanwhile, Pfizer and Covaxin are also the famous COVID-19 vaccines. Many other vaccines have entered into the general vaccination stage. Hence thanks to the health scientists.

### 8. Concluding remarks and future directions

Before coming to the conclusions and suggestions extracted from this literature survey, it looks good to mention here a quotation displayed on the WHO website (12th January 2021) that reads “With a fast-moving pandemic, no one...”
is safe, unless everyone is safe”. This work aimed to present a sequential form of literature confined to the initial stage of the COVID-19 pandemic, followed by diagnosis and drug repurposing, and finally good news of having reached a level of vaccination as the near end to the 2020 apocalyptic time. In the several approaches brought to light through this survey, it is to mention here that viral strains are never stagnant, they keep on changing their functionality concerning the environment. Hence, scientists should be ready to encounter any type of pandemic like COVID-19 in the future. Very recently the second type of coronaviral strain has regenerated the COVID-19 fear-like situation. Several countries have restarted lockdown strategies and physical distancing to prevent the people from this second coronavirus strain, which has 70% more communicability as compared to the previous form. Therefore, having reached the vaccination stage and bringing COVID-19 to control doesn’t mean that we are safe. Some of the directions need to ponder as listed below:

i. Going through drug repurposing and virtual screening results, it is evident that such research fields should be boosted to get more evolved in terms of machine learning.

ii. Non-clinical spectroscopic viral analysis should be made as advanced as possible so that RT-PCR’s less reliability gets replaced by reliable testing.

iii. As it is a fact that protection from any infectious disease cannot be demonstrated for any specific available right, therefore further development is required to bring forth a highly efficacious vaccine.

iv. Antibodies rendered towards S protein may offer some protective way out against SARS. On the other hand, it is acceptable that such high antibody titers are unable to defend the SARS-CoV challenge.

v. In case of the outbreak of another epidemic or pandemic, research and funding for the development of vaccines must be a priority.

vi. SARS-CoV pandemic caused lakhs of deaths, and it is expected this viral infection may now jump to animals, suggesting that another pandemic may occur.

vii. The world is still waiting for a 100% efficient vaccine. Let mucosal immunization, T-cell immunity, and attenuated SARS-CoV vaccines be the new future directions in this type of research.

Conflict of interest statement

There is no conflict of interest for this study.

References


[7] Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of


[61] El-Aziz TMA, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus
Advanced Chemicobiology Research

Volume 1 Issue 1|2021| 53


ClinicalTrials.gov Identifier: NCT04130594, 2019.


